Regeneron Pharmaceuticals, Inc. Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.46 Intrinsic Value $882.02median of 6 methods · middle span $714-$2,896based on filings through 30 Jun 2026 Market Price $734.81Price as of 1 Oct 2026 UndervaluedIntrinsic value is 20% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $75.7B Enterprise Value $75.2B Shares Outstanding 105.5M diluted Moat Rating Wide Next Earnings Date28 Oct 2026 Last ex-dividend18 Aug 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Regeneron entered the second half of 2026 with strong commercial momentum: second-quarter revenue increased 17% to $4.3 billion, while global Dupixent, U.S. EYLEA HD and global Libtayo sales increased 38%, 52% and 30%, respectively. This breadth and a clinical portfolio of approximately 50 assets support durable growth potential. The balanced rating reflects material development risk demonstrated by fianlimab's Phase 3 melanoma miss and uncertainty around converting late-stage programs such as cemdisiran into approved, commercially meaningful products. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$641.00 Mean target$833.65 High · most bullish analyst$1,030.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $641.0020% Commercial growth decelerates materially, EYLEA HD cannot fully offset legacy retinal-franchise pressure, and additional pivotal or regulatory setbacks reduce confidence in pipeline replacement value. A negative or delayed cemdisiran outcome and further fianlimab disappointment would reinforce the risk that research breadth does not translate into near-term approvals. The price target is an internal downside-scenario judgment. Base CaseCentral scenario $833.6555% Matches the consensus meanDupixent remains the principal growth engine, EYLEA HD continues converting the retinal franchise, and Libtayo contributes additional diversification, but growth moderates from the unusually strong second-quarter rates. Cemdisiran receives a decision on approximately the disclosed schedule, while pipeline attrition remains normal for biotechnology development. Bull CaseUpside scenario $1,030.0025% Sustained double-digit growth across Dupixent, EYLEA HD and Libtayo combines with successful cemdisiran approval and productive conversion of the approximately 50-asset clinical portfolio. Commercial diversification offsets pressure on legacy EYLEA, and the fianlimab setback proves program-specific rather than indicative of broader pipeline productivity. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |